Milan, Italy — July 12, 2026 — The International Conference on Lymphocyte Engineering (ICLE), distinguished as the only international conference specifically focused on the research and clinical translation of gene therapy, cell therapy, genome engineering, and immunotherapy, is set to convene its 6th edition in Milan, Italy, from July 15, 2026.
Core Scientific Focus on Lymphocyte Engineering
The International Conference on Lymphocyte Engineering (ICLE) will serve as a crucial gathering for leading researchers, clinicians, and industry professionals dedicated to advancing gene, cell, and immune therapies. The core scientific program will address Lymphocyte Engineering Technologies, encompassing methodologies used to modify lymphocytes for therapeutic purposes. Key areas include CAR/TCR mRNA therapies, which explore transient expression for therapeutic effects, and in vivo T-cell engineering, focusing on technologies for precise genetic modification of lymphocytes directly within the body.
Further discussions will encompass advanced TCR engineering, non-viral gene targeting, and genome editing for allogeneic ACT. The engineering of alternative leukocytes, such as Gamma-Delta T cells, iNKT cells, NK cells, B cells, and macrophages, will also be a significant area of development and discussion.
Clinical Translation and Regulatory Context
A significant segment of ICLE will be dedicated to Therapeutic Applications & Clinical Translation, highlighting the practical application of engineered lymphocytes in treating a range of diseases. This will cover strategies for targeting various cancers, including solid tumors and hematological malignancies, as well as fighting infections and autoimmune diseases. The program will also extend to cardiovascular diseases and genetic disorders, showcasing the broad potential of lymphocyte engineering.
Emphasis will be placed on translating research into clinical practice, exploring novel clinical approaches, combination therapies, and real-world experience. Regulatory aspects pertinent to lymphocyte engineering will be addressed, underscoring the path from discovery to patient care and the implications for patient outcomes.
Audience Engagement and Program Highlights
The conference is tailored for scientists and physicians with an interest in the engineering of lymphocytes for the treatment of cancer, autoimmune diseases, and other conditions. It will feature keynote lectures, plenary sessions, and poster presentations delivered by international experts. Unique session formats, such as "The Researcher's Journey" and "Expert-Led Inspiration," are designed to support and engage early career professionals, fostering their growth and integration into the field.
The event will bridge the gap between research and real-world application, offering scientific and clinical insights. The Kenes Group, a professional conference organizer renowned for its expertise in managing international medical and scientific events, developed and organizes ICLE as part of its portfolio of proprietary conferences.
For further information regarding the program and registration, interested parties may visit the official website at https://lymphocyte.kenes.com.